161 related articles for article (PubMed ID: 37997010)
1. Intestine-Targeted Explosive Hydrogel Microsphere Promotes Uric Acid Excretion for Gout Therapy.
Tang Y; Du Y; Ye J; Deng L; Cui W
Adv Mater; 2024 Jan; 36(3):e2310492. PubMed ID: 37997010
[TBL] [Abstract][Full Text] [Related]
2. Intestinal uric acid excretion contributes to serum uric acid decrease during acute gout attack.
Zhao T; Cao L; Lin C; Xu R; Du X; Zhou M; Yang X; Wan W; Zou H; Zhu X
Rheumatology (Oxford); 2023 Dec; 62(12):3984-3992. PubMed ID: 37042723
[TBL] [Abstract][Full Text] [Related]
3. A widely distributed gene cluster compensates for uricase loss in hominids.
Liu Y; Jarman JB; Low YS; Augustijn HE; Huang S; Chen H; DeFeo ME; Sekiba K; Hou BH; Meng X; Weakley AM; Cabrera AV; Zhou Z; van Wezel G; Medema MH; Ganesan C; Pao AC; Gombar S; Dodd D
Cell; 2023 Aug; 186(16):3400-3413.e20. PubMed ID: 37541197
[TBL] [Abstract][Full Text] [Related]
4. The Role of the Intestine in the Development of Hyperuricemia.
Yin H; Liu N; Chen J
Front Immunol; 2022; 13():845684. PubMed ID: 35281005
[TBL] [Abstract][Full Text] [Related]
5. Oral uricase eliminates blood uric acid in the hyperuricemic pig model.
Szczurek P; Mosiichuk N; Woliński J; Yatsenko T; Grujic D; Lozinska L; Pieszka M; Święch E; Pierzynowski SG; Goncharova K
PLoS One; 2017; 12(6):e0179195. PubMed ID: 28594873
[TBL] [Abstract][Full Text] [Related]
6. Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout.
Tan PK; Farrar JE; Gaucher EA; Miner JN
Mol Biol Evol; 2016 Sep; 33(9):2193-200. PubMed ID: 27352852
[TBL] [Abstract][Full Text] [Related]
7. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
Ganson NJ; Kelly SJ; Scarlett E; Sundy JS; Hershfield MS
Arthritis Res Ther; 2006; 8(1):R12. PubMed ID: 16356199
[TBL] [Abstract][Full Text] [Related]
8. ABCG2 as a therapeutic target candidate for gout.
Fujita K; Ichida K
Expert Opin Ther Targets; 2018 Feb; 22(2):123-129. PubMed ID: 29264928
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout.
Sundy JS; Ganson NJ; Kelly SJ; Scarlett EL; Rehrig CD; Huang W; Hershfield MS
Arthritis Rheum; 2007 Mar; 56(3):1021-8. PubMed ID: 17328081
[TBL] [Abstract][Full Text] [Related]
10. Recent insights into the pathogenesis of hyperuricaemia and gout.
Riches PL; Wright AF; Ralston SH
Hum Mol Genet; 2009 Oct; 18(R2):R177-84. PubMed ID: 19808794
[TBL] [Abstract][Full Text] [Related]
11. Development of a novel anti-inflammatory recombinant uricase with extended half-life for gout therapy.
Zhang Z; Fu N; Li Q; Quan J
Biochem Biophys Res Commun; 2023 Jul; 666():115-121. PubMed ID: 37182286
[TBL] [Abstract][Full Text] [Related]
12. PEG-uricase in the management of treatment-resistant gout and hyperuricemia.
Sherman MR; Saifer MG; Perez-Ruiz F
Adv Drug Deliv Rev; 2008 Jan; 60(1):59-68. PubMed ID: 17826865
[TBL] [Abstract][Full Text] [Related]
13. Electrochemical analysis of uric acid excretion to the intestinal lumen: Effect of serum uric acid-lowering drugs and 5/6 nephrectomy on intestinal uric acid levels.
Fujita K; Yamada H; Iijima M; Ichida K
PLoS One; 2019; 14(12):e0226918. PubMed ID: 31891613
[TBL] [Abstract][Full Text] [Related]
14. Oral Treatment With an Engineered Uricase, ALLN-346, Reduces Hyperuricemia, and Uricosuria in Urate Oxidase-Deficient Mice.
Pierzynowska K; Deshpande A; Mosiichuk N; Terkeltaub R; Szczurek P; Salido E; Pierzynowski S; Grujic D
Front Med (Lausanne); 2020; 7():569215. PubMed ID: 33330529
[TBL] [Abstract][Full Text] [Related]
15. A Therapeutic Uricase with Reduced Immunogenicity Risk and Improved Development Properties.
Nyborg AC; Ward C; Zacco A; Chacko B; Grinberg L; Geoghegan JC; Bean R; Wendeler M; Bartnik F; O'Connor E; Gruia F; Iyer V; Feng H; Roy V; Berge M; Miner JN; Wilson DM; Zhou D; Nicholson S; Wilker C; Wu CY; Wilson S; Jermutus L; Wu H; Owen DA; Osbourn J; Coats S; Baca M
PLoS One; 2016; 11(12):e0167935. PubMed ID: 28002433
[TBL] [Abstract][Full Text] [Related]
16. Self-Cascade Uricase/Catalase Mimics Alleviate Acute Gout.
Lin A; Sun Z; Xu X; Zhao S; Li J; Sun H; Wang Q; Jiang Q; Wei H; Shi D
Nano Lett; 2022 Jan; 22(1):508-516. PubMed ID: 34968071
[TBL] [Abstract][Full Text] [Related]
17. Diabetes insipidus in uricase-deficient mice: a model for evaluating therapy with poly(ethylene glycol)-modified uricase.
Kelly SJ; Delnomdedieu M; Oliverio MI; Williams LD; Saifer MGP; Sherman MR; Coffman TM; Johnson GA; Hershfield MS
J Am Soc Nephrol; 2001 May; 12(5):1001-1009. PubMed ID: 11316859
[TBL] [Abstract][Full Text] [Related]
18. Preparation of PEGylated uricase attached magnetic nanowires and application for uric acid oxidation.
Kilimci U; Uygun DA
J Biotechnol; 2023 Aug; 373():12-19. PubMed ID: 37343601
[TBL] [Abstract][Full Text] [Related]
19. ABCG2 dysfunction increases serum uric acid by decreased intestinal urate excretion.
Takada T; Ichida K; Matsuo H; Nakayama A; Murakami K; Yamanashi Y; Kasuga H; Shinomiya N; Suzuki H
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):275-81. PubMed ID: 24940679
[TBL] [Abstract][Full Text] [Related]
20. The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion.
Hoque KM; Dixon EE; Lewis RM; Allan J; Gamble GD; Phipps-Green AJ; Halperin Kuhns VL; Horne AM; Stamp LK; Merriman TR; Dalbeth N; Woodward OM
Nat Commun; 2020 Jun; 11(1):2767. PubMed ID: 32488095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
